See more : Arribatec Solutions ASA (ARR.OL) Income Statement Analysis – Financial Results
Complete financial analysis of SenesTech, Inc. (SNES) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SenesTech, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Longeveron Inc. (LGVN) Income Statement Analysis – Financial Results
- Shanghai Environment Group Co., Ltd (601200.SS) Income Statement Analysis – Financial Results
- Namsung Corp. (004270.KS) Income Statement Analysis – Financial Results
- CNS Co.,Ltd (4076.T) Income Statement Analysis – Financial Results
- Toga Limited (TOGL) Income Statement Analysis – Financial Results
SenesTech, Inc. (SNES)
About SenesTech, Inc.
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19M | 1.02M | 576.00K | 258.00K | 143.00K | 297.00K | 52.00K | 318.00K | 241.00K | 199.00K |
| Cost of Revenue | 654.00K | 555.00K | 356.00K | 281.00K | 101.00K | 241.00K | 45.00K | 196.00K | 0.00 | 0.00 |
| Gross Profit | 539.00K | 464.00K | 220.00K | -23.00K | 42.00K | 56.00K | 7.00K | 122.00K | 241.00K | 199.00K |
| Gross Profit Ratio | 45.18% | 45.53% | 38.19% | -8.91% | 29.37% | 18.86% | 13.46% | 38.36% | 100.00% | 100.00% |
| Research & Development | 1.23M | 1.86M | 1.95M | 1.49M | 1.91M | 2.40M | 3.19M | 2.71M | 7.22M | 3.20M |
| General & Administrative | 6.70M | 7.59M | 7.22M | 6.44M | 0.00 | 9.53M | 9.13M | 8.13M | 8.67M | 2.70M |
| Selling & Marketing | 317.00K | 631.00K | 584.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.02M | 8.28M | 7.22M | 6.44M | 8.42M | 9.53M | 9.13M | 8.13M | 8.67M | 2.70M |
| Other Expenses | 27.00K | -26.00K | -24.00K | -24.00K | 266.00K | 21.00K | 87.00K | -31.00K | -678.00K | 31.00K |
| Operating Expenses | 8.27M | 10.14M | 9.15M | 7.91M | 10.33M | 11.94M | 12.32M | 10.83M | 15.89M | 5.90M |
| Cost & Expenses | 8.93M | 10.69M | 9.51M | 8.19M | 10.43M | 12.18M | 12.37M | 10.83M | 15.89M | 5.90M |
| Interest Income | 26.00K | 7.00K | 4.00K | 3.00K | 45.00K | 25.00K | 29.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.00K | 2.00K | 11.00K | 28.00K | 42.00K | 74.00K | 86.00K | 87.00K | 855.00K | 632.00K |
| Depreciation & Amortization | 135.00K | 183.00K | 303.00K | 288.00K | 413.00K | 447.00K | 391.00K | 196.00K | 182.00K | 125.00K |
| EBITDA | -7.57M | -9.51M | -7.95M | -7.62M | -9.56M | -11.39M | -11.81M | -10.51M | -17.14M | -6.44M |
| EBITDA Ratio | -634.62% | -951.23% | -1,550.35% | -3,065.50% | -6,687.41% | -3,834.01% | -22,709.62% | -3,255.03% | -6,697.51% | -2,784.42% |
| Operating Income | -7.73M | -9.67M | -8.93M | -7.93M | -10.29M | -11.88M | -12.32M | -10.52M | -15.65M | -5.70M |
| Operating Income Ratio | -648.11% | -949.36% | -1,551.04% | -3,074.81% | -7,193.71% | -4,000.00% | -23,684.62% | -3,306.92% | -6,491.70% | -2,862.81% |
| Total Other Income/Expenses | 22.00K | -21.00K | 666.00K | -4.00K | 269.00K | -28.00K | 30.00K | -279.00K | -2.53M | -1.50M |
| Income Before Tax | -7.71M | -9.70M | -8.27M | -7.94M | -10.02M | -11.91M | -12.29M | -10.80M | -18.17M | -7.20M |
| Income Before Tax Ratio | -646.27% | -951.42% | -1,435.42% | -3,076.36% | -7,005.59% | -4,009.43% | -23,626.92% | -3,394.65% | -7,540.66% | -3,618.09% |
| Income Tax Expense | 0.00 | 19.00K | -292.00K | -239.00K | 308.00K | 46.00K | 173.00K | 56.00K | 177.00K | 663.00K |
| Net Income | -7.71M | -9.71M | -7.98M | -7.70M | -10.33M | -11.91M | -12.29M | -10.80M | -18.17M | -7.20M |
| Net Income Ratio | -646.27% | -953.29% | -1,384.72% | -2,983.72% | -7,220.98% | -4,009.43% | -23,626.92% | -3,394.65% | -7,540.66% | -3,618.09% |
| EPS | -11.51 | -186.39 | -171.04 | -614.56 | -1.90K | -245.50 | -450.00 | -672.84 | -1.09K | -403.93 |
| EPS Diluted | -115.10 | -186.39 | -171.04 | -614.56 | -1.90K | -245.50 | -450.00 | -672.84 | -1.09K | -403.93 |
| Weighted Avg Shares Out | 669.85K | 52.12K | 46.63K | 12.53K | 5.43K | 48.51K | 27.30K | 16.04K | 16.65K | 17.83K |
| Weighted Avg Shares Out (Dil) | 66.99K | 52.12K | 46.63K | 12.53K | 5.43K | 48.51K | 27.30K | 16.04K | 16.65K | 17.83K |
SenesTech, Inc. (SNES) Q3 2024 Earnings Call Transcript
SenesTech, Inc. (NASDAQ:SNES ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Robert Blum - Lytham Partners Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Operator Good day and welcome to...
SenesTech Announces Third Quarter 2024 Financial Results
Record Revenue and Margin Performance PHOENIX , Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat...
SenesTech Launches Evolve™ Rodent Birth Control on Walmart Marketplace
Significantly Expanding Market Reach PHOENIX , Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), a leader in fertility control solutions for managing animal pest populations, is excited to announce a significant expansion in the distribution...
SenesTech to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX , Nov. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its third quarter 2024, ended September 30, 2024, after...
Evolve™ Registered in Hong Kong; Offering a Revolutionary Non-Lethal Rodent Control Solution
PHOENIX , Oct. 31, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), the leader in birth control to manage rodent pest populations, today announces the successful registration of Evolve™ in Hong Kong. A Sustainable and Humane Approach to Rodent Control Hong Kong...
New York City to Pursue Rat Contraception Pilot Program
PHOENIX , Oct. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), the leader in birth control to manage rodent pest populations, today announces that the New York City Council has approved a bill to implement a rat contraception pilot program....
SenesTech to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
PHOENIX , Sept. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today it will participate in a webcasted presentation and host...
SenesTech Announces Closing of Warrant Exercise for $2.3 Million in Gross Proceeds
PHOENIX , Aug. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today the closing of an exercise...
SenesTech, Inc. (SNES) Q2 2024 Earnings Call Transcript
SenesTech, Inc. (NASDAQ:SNES ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Robert Blum – Lytham Partners Joel Fruendt – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Operator Good afternoon,...
SenesTech Announces Second Quarter 2024 Financial Results
Record Revenue and Margin Performance PHOENIX , Aug. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth...
Source: https://incomestatements.info
Category: Stock Reports